 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 GLOBE NEWSWIRE -- Assembly Biosciences, Inc. Nasdaq: ASMB and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus HBV core protein modulators. Door Pharmaceuticals innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bios current portfolio. 